ETF overview
VanEck Pharmaceutical ETF (PPH) seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the MVIS US Listed Pharmaceutical 25 Index (MVPPHTR), which is intended to track the overall performance of companies involved in pharmaceuticals, including pharmaceutical research and development as well a production, marketing and sales of pharmaceuticals.
Fund facts
- Expense ratio
- 0.36%
- Fund assets
- 1.13B USD (all share classes)
- Issuer
- VanEck
- Inception date
- Dec 20, 2011
- Number of holdings
- 25
Breakdown
Holdings (25)
| Name | Ticker | Weight |
|---|---|---|
| Eli Lilly & Co | LLY | 21.47% |
| Merck & Co Inc | MRK | 12.77% |
| Novo Nordisk A/S | NVO | 5.56% |
| Pfizer Inc | PFE | 5.11% |
| Mckesson Corp | MCK | 4.86% |
| Teva Pharmaceutical Industries Ltd | TEVA | 4.73% |
| Cencora Inc | COR | 4.58% |
| Bristol-Myers Squibb Co | BMY | 4.53% |
| Gsk Plc | GSK | 4.37% |
| Haleon Plc | HLN | 3.91% |
| and 12 more | ||
Similar ETFs
- Portfolio Building Block World Pharma and Biotech Index ETFPBPH · Overlap 48% · Expense ratio 0.13%
- iShares U.S. Pharmaceuticals ETFIHE · Overlap 46% · Expense ratio 0.37%
- iShares Global Healthcare ETFIXJ · Overlap 40% · Expense ratio 0.38%
- State Street Health Care Select Sector SPDR ETFXLV · Overlap 36% · Expense ratio 0.08%
- First Trust Nasdaq Pharmaceuticals ETFFTXH · Overlap 36% · Expense ratio 0.60%
- Tema Heart & Health ETFHRTS · Overlap 36% · Expense ratio 0.99%
- iShares U.S. Healthcare ETFIYH · Overlap 33% · Expense ratio 0.37%
- Fidelity MSCI Health Care Index ETFFHLC · Overlap 33% · Expense ratio 0.08%
Overlap is the share of assets the two funds hold in common.
Historical returns do not guarantee future returns. This is not investment advice.
- Expense ratio
- 0.36%
- Fund assets
- 1.13B USD (all share classes)
- Issuer
- VanEck
- Inception date
- Dec 20, 2011
- Number of holdings
- 25
| Name | Ticker | Weight |
|---|---|---|
| Eli Lilly & Co | LLY | 21.47% |
| Merck & Co Inc | MRK | 12.77% |
| Novo Nordisk A/S | NVO | 5.56% |
| Pfizer Inc | PFE | 5.11% |
| Mckesson Corp | MCK | 4.86% |
| Teva Pharmaceutical Industries Ltd | TEVA | 4.73% |
| Cencora Inc | COR | 4.58% |
| Bristol-Myers Squibb Co | BMY | 4.53% |
| Gsk Plc | GSK | 4.37% |
| Haleon Plc | HLN | 3.91% |
| and 12 more | ||
VanEck Pharmaceutical ETF (PPH) seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the MVIS US Listed Pharmaceutical 25 Index (MVPPHTR), which is intended to track the overall performance of companies involved in pharmaceuticals, including pharmaceutical research and development as well a production, marketing and sales of pharmaceuticals.
- Portfolio Building Block World Pharma and Biotech Index ETFPBPH · Overlap 48% · Expense ratio 0.13%
- iShares U.S. Pharmaceuticals ETFIHE · Overlap 46% · Expense ratio 0.37%
- iShares Global Healthcare ETFIXJ · Overlap 40% · Expense ratio 0.38%
- State Street Health Care Select Sector SPDR ETFXLV · Overlap 36% · Expense ratio 0.08%
- First Trust Nasdaq Pharmaceuticals ETFFTXH · Overlap 36% · Expense ratio 0.60%
- Tema Heart & Health ETFHRTS · Overlap 36% · Expense ratio 0.99%
- iShares U.S. Healthcare ETFIYH · Overlap 33% · Expense ratio 0.37%
- Fidelity MSCI Health Care Index ETFFHLC · Overlap 33% · Expense ratio 0.08%
Overlap is the share of assets the two funds hold in common.
Unlock all ETF data
Sign up for FreeUnlock all ETF data
Sign up for Free